Loading
Crinetics Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Jun 2023.
Crinetics Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Crinetics Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 67 filings were filed, from 16 insiders.
All open-market trades in the period are sales: 10 sales worth €4.3M, by 6 insiders, with no purchase on record. No amount is published for 2 filings, which the totals therefore leave out. At €2.9M, the sale published on 10 April 2026 by Knight Jeff E. is the largest of the period.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 67 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 3 purchases and 70 sales. The 10-K for the year ended 31 December 2025 shows 7.7 m USD of revenue and -465.3 m USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
237
Thresholds
n/a
Buy Volume
€24M
3 ops. · all time
Sell Volume
€14M
70 ops. · all time
Who traded when
BuySaleJeff E. Knight4 sales
Richard Scott Struthers4 sales
Stephanie Okey3 sales
Coelho Rogerio Vivaldi2 sales
Dana Pizzuti2 sales
Stephen F. Betz2 sales
+2 other insiders
Since the insiders bought
- +123.1%Entry US$20.32 · Close at T+365 US$45.33
- -15.1%Entry US$21.02 · Close at T+365 US$17.85
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Crinetics Pharmaceuticals, Inc. Hold (neutral), based on 8 analysts. Average price target: US$85.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,567 of 24,148 companies
36.4
score / 100
Value22
Quality51
FCF yld-4.3%
Earn yld-5.2%
EV/EBITDA·
ROE-42%
Gross mgn86%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$84.95
Analyst consensus
8 analystsHold
US$85.00Target US$85.00(+0%)US$85.00
Income statement
RevenueUS$7.7M
Gross profitUS$6.6M86% margin
EBITDA-US$512.9M-6664% margin
Net income-US$465.3M-6046.2% margin
Valuation
PER (forward)-21.2x
P/Book7.5x
Beta0.09
Balance sheet & cash
Market capUS$9B
Total debtUS$48.5M
Free Cash Flow-US$383.7M
Debt / Equity4%
Profitability & ownership
ROE-42.4%
ROA-26.3%
% insiders1.1%
% institutions119.2%
Last declaration on 1 September 2026
Declarations237 total
16,300 shares@ US$85.000.015% mcap73.3% of flowCommon StockSEC:0001628280-26-059900:0
110,000 shares@ US$85.000.10% mcap9.4% of flowCommon StockSEC:0001628280-26-059882:4
6,400 shares@ US$85.000.0059% mcap36.0% of flowCommon StockSEC:0001628280-26-059905:0
5,925 shares@ US$85.000.0055% mcap26.7% of flowCommon StockSEC:0001628280-26-059900:1
58,286 shares@ US$85.000.054% mcap28.4% of flowCommon StockSEC:0001628280-26-059884:0
79,650 shares@ US$85.000.074% mcap38.8% of flowCommon StockSEC:0001628280-26-059884:1
248,043 shares@ US$85.000.23% mcap21.3% of flowCommon StockSEC:0001628280-26-059882:0
1,000 shares@ US$85.000.0009% mcap0.1% of flowCommon StockSEC:0001628280-26-059882:1
136,805 shares@ US$85.000.13% mcap11.8% of flowCommon StockSEC:0001628280-26-059882:2
106,000 shares@ US$85.000.098% mcap9.1% of flowCommon StockSEC:0001628280-26-059882:3
100,000 shares@ US$85.000.092% mcap8.6% of flowCommon StockSEC:0001628280-26-059882:5
111,100 shares@ US$85.000.10% mcap9.5% of flowCommon StockSEC:0001628280-26-059882:6
80,000 shares@ US$85.000.074% mcap6.9% of flowCommon StockSEC:0001628280-26-059882:10
176,663 shares@ US$85.000.16% mcap15.2% of flowCommon StockSEC:0001628280-26-059882:11
7,956 shares@ US$85.000.0074% mcap9.6% of flowCommon StockSEC:0001628280-26-059883:0
71,471 shares@ US$85.000.066% mcap86.6% of flowCommon StockSEC:0001628280-26-059883:1
1,669 shares@ US$85.000.0015% mcap4.5% of flowCommon StockSEC:0001628280-26-059885:0
34,000 shares@ US$85.000.031% mcap92.3% of flowCommon StockSEC:0001628280-26-059885:1
16,300 shares@ US$85.000.015% mcap73.3% of flowCommon StockSEC:0001628280-26-059901:0
5,925 shares@ US$85.000.0055% mcap26.7% of flowCommon StockSEC:0001628280-26-059901:1
22,836 shares@ US$85.000.021% mcap54.6% of flowCommon StockSEC:0001628280-26-059902:0
5,925 shares@ US$85.000.0055% mcap14.2% of flowCommon StockSEC:0001628280-26-059902:1
16,300 shares@ US$85.000.015% mcap73.3% of flowCommon StockSEC:0001628280-26-059904:0
5,925 shares@ US$85.000.0055% mcap26.7% of flowCommon StockSEC:0001628280-26-059904:1
5,925 shares@ US$85.000.0055% mcap33.4% of flowCommon StockSEC:0001628280-26-059905:1
25 of 237 declarations
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a U.S.-based biopharmaceutical company headquartered in San Diego, California, United States. The company was founded in 2008 by scientists with deep experience in endocrine drug discovery, and it has built its business around internally discovered, small-molecule therapies for endocrine diseases and endocrine-related tumors. Over time, Crinetics has evolved from a clinical-stage developer into a company with a commercial asset, while still maintaining a broad research-and-development pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1658247/000095017025057467/crnx_ars_2024.pdf?utm_source=openai))
Crinetics’ core business is focused on precision endocrinology. The company develops orally administered, nonpeptide therapies aimed at important hormone-receptor pathways, with programs spanning pituitary disorders, adrenal diseases, and selected neuroendocrine tumors. Its lead product, PALSONIFY™ (paltusotine), reached a major inflection point when it received FDA approval in September 2025 for adult acromegaly, making it the company’s first approved and commercialized therapy. Management also highlights a disclosed pipeline of 10+ programs, including atumelnant, which is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, as well as CRN09682, a nonpeptide drug conjugate for SST2-expressing tumors. ([crinetics.com](https://crinetics.com/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Crinetics is positioned as a niche endocrine specialist with a differentiated scientific platform and a strong focus on diseases where treatment options remain limited. That specialization can be attractive in biotech because it supports deep clinical expertise, potentially meaningful pricing power in rare-disease markets, and a clearer path to commercialization in targeted patient populations. The company also disclosed the creation of Crinetics Pharmaceuticals Europe GmbH, signaling an incremental effort to support development, regulatory, and pre-commercial activities outside the United States. ([ir.crinetics.com](https://ir.crinetics.com/news/news-details/2024/EY-ANNOUNCES-SCOTT-STRUTHERS-PH-D--CEO-AND-FOUNDER-OF-CRINETICS-PHARMACEUTICALS-AS-AN-ENTREPRENEUR-OF-THE-YEAR-2024-PACIFIC-SOUTHWEST-AWARD-WINNER-06-18-2024/default.aspx?utm_source=openai))
Recent company updates underscore a business in transition. During 2025 and 2026, Crinetics reported continued launch execution for PALSONIFY, further advancement of atumelnant in clinical development, and progress across late-stage programs in CAH and other endocrine indications. The company also completed a public equity offering in 2026 to support commercial launch activities and R&D, reinforcing its capital-intensive profile. For French, Belgian, and Swiss investors, CRNX is therefore a NASDAQ-listed U.S. healthcare name with a mix of commercial potential and classic biotech risks, including regulatory execution, clinical readouts, manufacturing dependence, and funding needs. ([crinetics.com](https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
